U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07717281) titled 'PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis' on July 13.
Brief Summary: Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies attack the neuromuscular junction, the site at which nerve cells communicate with muscle fibres, impairing signal transmission and causing fluctuating muscle weakness that worsens with sustained activity. In most patients this dysfunction is reversible and improves with treatments that suppress the immune response. About 10 to 15 percent of patients do not respond adequately to standard therapy, and the mechanisms of this refractory course remain unclear.
The st...